Program Director/Principal Investigator (Last, First, Middle): Puvvada, Soham

Program Director/Principal Investigator (Last, First, Middle): Puvvada, Soham

Program Director/Principal Investigator (Last, First, Middle): Puvvada, Soham

BIOGRAPHICAL SKETCH
NAME
Soham D. Puvvada MD / POSITION TITLE
Assistant Professor of Medicine, Lymphoma.
Division of Hematology-Oncology,
University of Arizona
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION / DEGREE
(if applicable) / YEAR(s) / FIELD OF STUDY
Florida Atlantic University, Boca Raton, Florida / BS / 05/95-05/98 / Nursing
University of Florida, Gainesville, Florida / 08/99-05/02 / Biomedical Engineering
University of South Florida College of Medicine, Tampa, Florida / MD / 08/02-05/06 / Medicine
University of North Carolina, Chapel Hill,
North Carolina / 06/06-06/09 / Residency in Internal Medicine
Duke University, Durham, North Carolina / 07/09-07/12 / Hematology/
Oncology
Fellowship

INSTRUCTIONS: The LRP Biographical Sketch may not exceed five pages. Follow the format on the sample provided.

  1. Positions and Honors

2012- present: Assistant Professor of Medicine, Lymphoma.

Division of Hematology & Oncology, Department of Medicine, University of Arizona, Tucson, AZ.

2010-2012: Post-Doctoral Research Fellow in Lymphoma Genomics Lab,

Institute of Genomic Sciences and Policy, Duke University, Durham, NC.

2009-2010: Clinical Fellow at Duke University Department of Hematology-Oncology, Durham NC

2006-2009: Internal Medicine Residency, University of North Carolina Chapel Hill, NC.

Honors:

2013:SWOG Young Investigator Award.

2013:Coltman Fellowship Award, The Hope Foundation.

2012:Robert Silber Memorial Research Award, Duke University

2011:American Society of Hematology Clinical Research Training Institute Career Development Award

2011:Best Research Presentation for 2nd year Fellow at Duke Oncology Annual Research Retreat

2006: Dean’s Award for Academic Excellence, University of South Florida.

1998: Phi Kappa Phi Scholar, Florida Atlantic University

1995-1998: National Dean’s List, Florida Atlantic University

Professional Memberships:

2012 -Member, Southwest Oncology Group.

2009 -Member, American Society of Clinical Oncology.

2009 -Member, American Society of Hematology.

2002 -Member, American College of Physicians.

2002 -Member, American Medical Association.

  1. Selected peer-reviewed publications (in chronological order).

 Puvvada SD et al. Prognostic implication of NF-κB and BCL3 activation in metastatic colorectal cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstract 11090).

 Tyler W Buckner, Soham Puvvada, Chirag Amin, and Nigel S. Key Differing Clot Distribution in Black Compared to White Patients Presenting with Acute Lower Extremity Deep Venous Thrombosis. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3819.

 Puvvada SD et al. NF-kB and Bcl-3 Activation Are Prognostic in Metastatic Colorectal Cancer. Oncology 2010; 78(3-4) 181-8. doi: 10.1159/000313697. Epub 2010 Apr 23 PMID 20414006 PMCID PMC2914399

 Puvvada Soham et al. Selective IKKβ Inhibition of the NF-Kappab Pathway Is An Effective Therapeutic Strategy In Lymphomas. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 1849

 Puvvada SD, et al. Emerging Frontiers in Therapeutics of Diffuse Large B cell Lymphoma: Epigenetics and B cell Receptor Signaling. J Cancer Therapy 2013 Jan 28, Journal ID 8901557

 Puvvada SD, et al. Molecular Classification, Pathway Addiction, and Therapeutic Targeting in Diffuse Large B cell Lymphoma. Cancer Genetics 2013 Jan 30, PMCID 24080457

 Schatz JH, Puvvada SD, Oricchio E, Wendel HG. Progress Against Follicular Lymphoma. Curr Opin Hematol. 2013 May 13. [Epub ahead of print] PMCID: 23673338

 Puvvada S, Miller T. Radiotherapy is not essential to Cure Diffuse Large B-cell Non-Hodgkin Lymphoma. Oncology, 2013 May Supplement.

 Soham Puvvada, Daniel Persky, Lora Inclan, Jonathan Schatz, Ellen Chase, Jose M Guillen-Rodriguez, Denise J Roe, Thomas Miller. Yttrium-90-Ibritumomab tiuxetan (Zevalin) radioimmunotherapy after cytoreduction with ESHAP chemotherapy in patients with relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results of a phase II study. ASH, December 2013 #4404

 Kevin R. Kelly, Daniel O. Persky, Daruka Mahadevan, Thomas P. Miller, Soham D. Puvvada, Kevin McDonagh, John Hayslip, Steven I. Park, Jia Ruan, Peter J. Rosen, Swaminathan Padmanabhan Iyer, Alexandra Stefanovic, Bin Zhang, Xiaofei Zhou, Claudio Dansky Ullmann, E. Jane Leonard, Jonathan W. Friedberg. Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. ASH, December 2013 #3027

 Paul M. Barr, Margaret M. Briehl, Steven H Bernstein, Jonathan W. Friedberg, Andrea Baran, Derick R. Peterson, Daniel Oscar Persky, Carla Casulo, Megan M. Herr, Jamie Littleton, Erin Cebula, Mark Schwartz, Soham D. Puvvada, Robert T Dorr, Richard I Fisher, Thomas P. Miller. Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study. ASH, December 2013 #89

 Lingxiao Li, Praechompoo Pongtornpipat, Soham D. Puvvada, Jonathan H. Schatz. Targeting MYC Expression with CDK Inhibitors Shows Potency In Preclinical Models Of High-Risk Diffuse Large B-Cell Lymphoma. ASH, December 2013 #1831

  • Soham Puvvada & Sandy Kurtin. Toxicity of targeted therapeutic agents in lymphoma and management: Part1: monoclonal antibodies and radioimmunotherapy. Int. J. Hematol. Oncol. (2014) 3(1), 1-11. manuscript in press.
  1. Clinical Trials:
  1. A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-199
  2. AbbVie: M13-364
  3. PI: Soham D. Puvvada MD
  1. An Extension Study of ABT-199 in Subjects with Advanced Lymphoproliferative Diseases
  2. AbbVie: M13-835
  3. PI: Soham D. Puvvada MD
  1. A Phase 2 Open-Label Study of the Efficacy of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the17p Deletion
  • AbbVie: M13-982
  • PI: Soham D. Puvvada MD
  1. A Phase II, Open-Label Study of Bortezomib (Velcade®), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas. Investigator initiated trial.
  • Millennium: X05260 / IRB 12-0288-04
  • PI: Soham D. Puvvada MD
  1. A Phase II Exploratory Study of PXD-101(Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma (stage 1).

Investigator initiated trial.

  • Spectrum: IRB 12-0288-04
  • PI: Soham D. Puvvada MD

6.A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab and Vincristine.

  • Millennium: #C14011 / WIRB #20110910
  • PI: Soham D. Puvvada MD.
  1. A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with

Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

AbbVie M12-175

  • PI: Soham D. Puvvada MD.
  1. Phase 1b, Escalating Dose Study of AVL-292, a Bruton’s Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia
  • AVL-292-003
  • PI: Thomas P. Miller MD
  • Co-PI: Soham D. Puvvada, MD
  1. SWOG 0801: A Phase II Study of Iodine-131 Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Follicular Non-Hodgkin’s Lymphoma
  • PI: Thomas P. Miller, MD
  • Co-PI: Soham D. Puvvada MD
  1. Phase II Trial of Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin's Lymphoma

Investigator initiated trial.

  • Spectrum (transferred from Biogen Idec): IRB 05-0303-04 / 106-P158
  • PI: Thomas P. Miller MD
  • Co-PI: Soham D. Puvvada MD
  1. SWOG 0816: A Phase II Trial of Response Adapted Therapy of Stage III-lV Hodgkin Lymphoma Using Early Interim FDGPET Imaging
  • PI: Thomas P. Miller, MD
  • Co-PI: Soham D. Puvvada MD
  1. SWOG 1001 A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)
  • PI: Thomas P. Miller, MD
  • Co-PI: Soham D. Puvvada MD
  1. SWOG 0806 A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)
  • PI: Thomas P. Miller, MD
  • Co-PI: Soham D. Puvvada MD
  1. CALGB 50604 Phase II Trial of Response- Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma
  • PI: Thomas P. Miller, MD
  • Co-PI: Soham D. Puvvada MD
  1. Research Support:

2011-2013:NHLBI Transfusion Medicine & Hematology 5T32HL007057 T32 Training grant. PI: Dr. Marilyn Telen.

2013-2014 CCSG – NCI P30 - Cyclin-Dependent Kinase Inhibition as a Synthetic Lethal Approach in High-Risk Diffuse Large C-Cell Lymphoma with Co-Expression of C-MYC and BCL2. PI: Dr. Dave Alberts.

2013-2015 Hope Foundation-Coltman Fellowship - Phase III trial of R-chemotherapy & Maintenance Rituximab with or without Ibrutinib in Newly Diagnosed Follicular Lymphoma